Interventional - Drug
The objective of the SCHOLAR-2 study is to evaluate whether is it safe and effective to continue trastuzumab in patients with early stage HER2 positive breast cancer who develop mild, minimally symptomatic or asymptomatic systolic left ventricular dysfunction.
The primary efficacy outcome will be the likelihood of completing trastuzumab as planned at its initiation.
The primary safety outcome will be left ventricular ejection fraction.
Interventional - Drug
Randomized clinical trial phase 2
Darryl Leong is a Scientist at PHRI, Director of the McMaster University and Hamilton Health Sciences Cardio-Oncology Program, Associate Professor, Department of Medicine (Cardiology), McMaster University, and Staff Cardiologist at Hamilton Health Sciences. He has methodological expertise in clinical epidemiology and clinical trials, and content expertise in physical frailty, echocardiography, and cardio-oncology. His research is supported by the CIHR, and he has published more than 150 manuscripts including all the leading internal medical and cardiovascular journals.
He graduated from the University of Adelaide Medical School with Deans Listing and Honours for academic excellence, completed his cardiology training, Doctor of Philosophy, Master of Public Health, and Master of Biostatistics degrees at the University of Adelaide in Australia, and completed a post-doctorate fellowship in cardiovascular imaging at the Leiden University Medical Centre in The Netherlands, before re-locating to Canada.
Filipe Cirne completed his medical degree at Universidade Federal do Rio Grande in Brazil (2012). His internal medicine and cardiology residency trainings were completed at Universidade Federal do Rio Grande do Sul, also in Brazil. Additionally he completed an echocardiography fellowship at Instituto de Cardiologia do Rio Grande do Sul, where he is currently completing a MSc.
His main research interests include cardio-oncology and structural heart disease. He is finishing an advanced echocardiography fellowship at McMaster University. Filipe is working on cardio-oncology research projects under the mentorship of Darryl Leong, including on the studies RADICAL-PC and SCHOLAR-2, and doing systematic reviews on prostate cancer risk factors and survivorship/CV outcomes.
Harry Klimis is a Clinical and Research Fellow at PHRI and McMaster University, supervised by Darryl Leong and Salim Yusuf. His training features an integrated cardio-oncology research and clinical program dedicated to understanding the evolution of cardiovascular risk factor patterns in healthy populations and people with cancer, and their association with CVD and mortality. Harry is an investigator in the RADICAL-PC and SCHOLAR-2 studies, and will be working on the PURE study.
Harry is an Australian cardiologist and completed both his MBBS and PhD at the University of Sydney. His research has primarily focused on primary prevention of cardiovascular disease and digital health interventions. Other research interests include cardio-oncology and echocardiography.
Sumathy Rangarajan has been Program Director, Global Health, since 2016, preceded by many years’ service at PHRI in other roles. She oversees the PURE study team, as well as the INVICTUS rheumatic AF treatment trial, the CANPWR pediatric weight management registry, and others.
She holds both a Bachelor of Science Degree and a Master of Science degree from Pune University in India.
Senior Research Coordinator
Maha Mushtaha has been employed by the Population Health Research Institute since 2011, working currently in the global health research group on the following studies: PURE, SCHOLAR-2 and TIMING. She has experience with site and database management of large, international observational studies as well as investigator-initiated clinical trials.
She holds a Bachelor of Science Degree from McMaster University and a Biotechnology Diploma from Mohawk College.
Back To Top